Eptinezumab for Migraines in Children and Adolescents

We are studying the long-term safety of eptinezumab in children and teens aged 6 to 17 who experience chronic or episodic migraines. This research aims to ensure the medication is safe for young patients.

6-12 months ≤5 visits Confirmation phase (III)No Placebo Cost Reimbursement Partially Remote Standard Medicines InjectionNeurologyPediatrics

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Vyepti

Vyepti is a medicine used to prevent migraine headaches in adults.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Eptinezumab

Eptinezumab is a substance that helps prevent migraine attacks by blocking a protein involved in migraine pain signaling.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Azienda Socio Sanitaria Locale N. 8 Di Cagliari

Neurologist

Cagliari, Italy

Azienda Ospedaliera Universitaria Meyer IRCCS

Neurologist

Florence, Italy

Giannina Gaslini Institute For Scientific Hospitalization And Care

Neurologist

Genoa, Italy

Sponsor: H. Lundbeck A/S

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.